Pramipexole (Mirapex)
Prescription medicine for Parkinson's disease and restless legs syndrome; it lowers prolactin but can cause impulse-control disorder.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Cabergoline vs Bromocriptine vs PramipexoleDETAILED OVERVIEW
What is Pramipexole (Mirapex)?
Pramipexole (Mirapex) is a prescription medicine approved in the United States since 1997 for Parkinson's disease and restless legs syndrome. It mimics the action of dopamine in the brain and lowers prolactin (a hormone that controls milk production) in the pituitary gland, which is why it is also used off-label after anabolic steroid use. According to case reports it may also increase sexual desire.
Its most serious risk is impulse-control disorder: pathological gambling, increased sexual urges, compulsive shopping or binge eating. The official prescribing information warns about it, and in Parkinson's disease it appeared in roughly one in five users. It can also cause sudden attacks of falling asleep and daytime drowsiness, and stopping it abruptly can bring withdrawal symptoms (anxiety, panic). It builds up in severe kidney failure, and its safety in pregnancy and breastfeeding has not been shown. Alcohol increases drowsiness and the risk of impulse-control disorder.
Mechanism
Non-ergot D3-D2 selective DA agonist (D3 > D2), pituitary prolactin suppression + sexual stimulation
Half-life
~8-12 hours
Onset
Prolactin reduction 2-4 h
Legal status
FDA + EMA Rx, HU + PL approved, WADA allowed
No anecdote collected yet.
Data console
Lab data
Weintraub D, Koester J, Potenza MN, et al. . Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients (DOMINION study). Arch Neurol. 2010;67(5):589-595..
Krüger TH, Haake P, Haverkamp J, Krämer M, Exton MS, Saller B, Mann K, Hartmann U, Schedlowski M . Effects of acute prolactin manipulation on sexual drive and function in males.. J Endocrinol.
Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, Zak RS, Kazmi U, Falck-Ytter Y, Shelgikar AV, Trotti LM, Walters AS . Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.. J Clin Sleep Med.
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Impulse-control disorder (ICD): pathological gambling, hypersexuality, compulsive shopping, binge eating – FDA black-box, dopamine-agonist class effect, warrants discontinuation.
- Sudden sleep attacks and daytime somnolence – driving and operating machinery may be hazardous, especially during titration.
- Orthostatic hypotension: dizziness, lightheadedness on standing, especially at dose initiation – rise slowly.
- Nausea, gastric upset, loss of appetite – common in the first days, mitigated by taking with food.
- Headache, fatigue, lethargy, and occasionally vivid dreams or hallucinations (the latter mainly at higher, Parkinson-level doses).
- Peripheral edema (leg swelling) – a dopamine-agonist class effect to watch for with longer use.
- Dopamine agonist withdrawal syndrome (DAWS) on abrupt discontinuation: anxiety, panic, sweating, pain, dysphoria – taper gradually.
Contraindications · 7
- History of impulse-control disorder or addiction (gambling, OCD-spectrum, hypersexuality) – markedly raises ICD risk, avoid.
- Severe renal impairment (CrCl <30 ml/min) without dose reduction – ~90% is excreted unchanged renally and accumulates.
- Concurrent antipsychotic therapy (D2/D3 antagonists) – direct mechanism conflict, mutually counteracting.
- Metoclopramide / domperidone (D2-antagonist antiemetics) – mechanism conflict, avoid; use a different antiemetic for nausea.
- Pregnancy and breastfeeding – no established safety, and prolactin suppression also inhibits lactation.
- Occupations or activities where sudden sleep onset is critical (professional driving, working at heights) – especially during titration.
- Combining with alcohol or other sedatives – increases somnolence, sleep attacks, and ICD risk.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients (DOMINION study)
Weintraub D, Koester J, Potenza MN, et al.
Effects of acute prolactin manipulation on sexual drive and function in males.
Krüger TH, Haake P, Haverkamp J, Krämer M, Exton MS, Saller B, Mann K, Hartmann U, Schedlowski M
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.
Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, Zak RS, Kazmi U, Falck-Ytter Y, Shelgikar AV, Trotti LM, Walters AS
Telegram
Have a question about Pramipexole (Mirapex)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.
